Advances in the Use of Positronic Radiomolecular Imaging Agents in the Diagnosis of Parkinson's Disease

DOI: https://doi.org/10.62517/jmhs.202405210

Author(s)

Ruofeng Yu1, Ruoyu Yu2, Yating Wu3, Shou Fang4,*

Affiliation(s)

1School of Chinese-Western Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China 2School of Law, Xiamen University Tan Kah Kee College, Zhangzhou, Fujian, China 3School of Humanities and Management, Fujian University of Traditional Chinese Medicine, Putian, Fujian, China 4Radiographic Imaging Management, Affiliatd Hospital of Putian University, Putian, Fujian, China *Corresponding Author.

Abstract

The objective of this study was to examine the potential of positron radioactive molecular imaging agents for the diagnosis of Parkinson's disease (PD). With the increasing prevalence of aging and the rising incidence of PD, early diagnosis is of paramount importance to enhance the quality of life of patients. In terms of research methods, this study analyzed the application of positron emission tomography (PET) and computed tomography (CT) technology and its combination with positron radioactive molecular imaging agents in the diagnosis of Parkinson's disease (PD), with particular emphasis on the use of glucose metabolism imaging agents, including 18F-fluoro-2-deoxy-D-glucose (18F-FDG). The findings of the study demonstrate that the integration of PET/CT technology with positron radioactive molecular imaging agents offers a comprehensive approach to the diagnosis of PD. This approach provides valuable functional and metabolic information about the brain of PD patients, and enables the accurate localization of lesions with high specificity and sensitivity, making it a highly effective and well-tolerated diagnostic tool. The utilization of positron radioactive molecular imaging agents in the diagnosis of PD has the potential to significantly enhance the accuracy and efficiency of diagnosis, thereby facilitating early detection and treatment of PD.

Keywords

Computed Tomography; Contrast Agents; Parkinson's Disease; Clinical Diagnosis

References

[1] Xiang Qi, Han Tao, Liu Anru, et al. Progress of positron emission tomography and computed tomography in the localization of epileptogenic foci in epilepsy etiology and prognosis prediction of epilepsy treatment. Journal of Epilepsy, 2024, 10 (02): 127-132. [2] Li SZ, Huang Q, Wu XJ, et al. Application of positron emission computed tomography in central nervous system drug development. Chinese Clinical Pharmacology and Therapeutics, 2024, 29 (03): 316-327. [3] LI Ling, WU Ping, WU Jianjun, et al. Study on the differential diagnostic value of PET imaging of dopamine transporters in Parkinson's disease and progressive supranuclear palsy. China Clinical Neuroscience, 2018, 26 (03): 262-268. [4] ZHANG Ge, YANG Wenjiang, LIU Yu. Progress of positron emission computed tomography imaging agents in the central dopamine system. Journal of Inorganic Chemistry, 2024, 40 (01): 54-70. [5] JIANG Ying, LEI Yilu, ZHANG Xingbo, et al. Clinical study of Ambroxol hydrochloride combined with dobasic hydrazide in the treatment of early-stage geriatric Parkinson's disease. China Prescription Drugs, 2024, 22 (02): 142-145. [6] CHEN Zhigeng, YAN Shaozhen, LU Jie. Research progress of machine learning based on positron emission computed tomography and magnetic resonance in the diagnosis of Alzheimer's disease. Chinese Journal of Geriatric Cardiovascular Disease, 2023, 25 (12): 1413-1415. [7] Deng Weisheng, Lou Yunlong, Su Zhongzhen. Application of positron emission computed tomography in the early diagnosis of Parkinson's disease patients. China Practical Medicine, 2018, 13 (07): 3-5. [8] Chang Peiye, Xue Jingting, Wang Chunmei, et al. Value of serum CKMT1A and NFL testing combined with (11)C-β-CFT PET/CT brain imaging in the diagnosis of Parkinson's disease. Chinese Journal of Gerontology, 2023, 43 (18): 4424-4427. [9] Natsumuguri. Mutalbek, Zhang Qizhou, Qin YD, et al. Study on the clinical value of (18)F-FDG, (11)C-CFT and (11)C-RAC PET/CT imaging in Parkinson's disease. Journal of Xinjiang Medical University, 2018, 41 (10): 1217-1222. [10] Yi Chang, Shi Xinchong, Xian Wenbiao, et al. Diagnosis and condition assessment of early Parkinson's disease by ^18F-DOPA brain PET imaging. Chinese Journal of Nuclear Medicine and Molecular Imaging,2018,38(11):731-735. [11] HUANG Kaihe, WU Liang, TIAN Youyong. Application of positron emission computed tomography in the diagnosis of Parkinson's disease. Medical Review, 2020, 26 (03): 559-564. [12] Xu Lu, Pang Hua, Liu Shuang, et al. Study on the differential diagnostic value of (11)C-β-CFT PET/CT and TCS testing for PD and APS. Modern Medicine and Health, 2023, 39 (19): 3247-3252+3256.